Two promising therapeutic candidates for long COVID have failed to demonstrate meaningful benefits in the largest controlled trial to date, potentially closing important research avenues while highlighting the stubborn complexity of post-viral syndromes. The metabolic dysfunction theory underlying these interventions may require fundamental reconsideration.
This randomized controlled trial involving 396 adults with persistent COVID symptoms found virtually identical recovery rates across all groups: 68% for both ursodeoxycholic acid and placebo, with metformin slightly lower at 64%. Participants received either metformin 1500mg daily, UDCA 900mg daily, or placebo for 14 days, with symptoms tracked over eight weeks using standardized scoring. The mean baseline symptom severity was substantial at 19.3 points, occurring an average of 9.8 months post-infection.
These null findings carry significant implications for long COVID research strategy. Metformin's failure challenges the metabolic dysfunction hypothesis that has driven much therapeutic development, given its established benefits for cellular energy metabolism and mitochondrial function. UDCA's ineffectiveness similarly questions whether bile acid signaling pathways meaningfully contribute to post-viral symptoms. The study's robust design—double-blind, placebo-controlled, with adequate sample size—makes these negative results particularly credible. However, the relatively short 14-day treatment period and focus on moderately affected patients may have limited detection of benefits in more severe cases. The high placebo response rate of 68% suggests substantial natural recovery occurs regardless of intervention, complicating future trial design and potentially indicating that current symptom measures capture normal healing processes rather than distinct pathological states requiring targeted therapy.